Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML3513

Sigma-Aldrich

Lorcaserin hydrochloride

≥98% (HPLC)

Sinonimo/i:

(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride, APD 356 hydrochloride, APD-356 hydrochloride, APD356 hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C11H14ClN·HCl
Numero CAS:
Peso molecolare:
232.15
Numero MDL:
Codice UNSPSC:
12352200
NACRES:
NA.04

Livello qualitativo

Saggio

≥98% (HPLC)

Stato

powder

Controllo stupefacenti

USDEA Schedule IV

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

H2O: 2 mg/mL, clear

Temperatura di conservazione

-10 to -25°C

Azioni biochim/fisiol

Lorcaserin is an orally active, potent and selective 5-hydroxytryptamine receptor (5-HT2C) agonist (human/rat Ki = 15 /29 nM) with 18- and 104-fold higher potency than 5-HT2A and 5-HT2B by cellular inositol phosphate accumulation assay (EC50 = 9, 168, 943 nM, respectively) and good selectivity over 5-HT1A/3/4C/5A/6/7 and a panel of 67 other GPCRs and ion channels. Chronic daily treatment to rats (4.5-18 mg/kg p.o. b.i.d.) maintained on a high fat diet causes reductions in food intake and body weight gain.

Avvertenza

Hygroscopic

Pittogrammi

Health hazardExclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Oral - Carc. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Lisa R Gerak et al.
Drug and alcohol dependence, 227, 108991-108991 (2021-09-06)
The opioid epidemic continues despite the availability of medications, including buprenorphine, for opioid use disorder (OUD); identifying novel and effective treatments is critical for decreasing the prevalence of OUD and ending this crisis. Buprenorphine alone does not markedly attenuate abuse-related
Yang He et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 41(26), 5734-5746 (2021-05-26)
Obesity is a serious global health problem because of its increasing prevalence and comorbidities, but its treatments are limited. The serotonin 2C receptor (5-HT2CR), a G-protein-coupled receptor, activates proopiomelanocortin (POMC) neurons in the arcuate nucleus of hypothalamus (ARH) to reduce
William J Thomsen et al.
The Journal of pharmacology and experimental therapeutics, 325(2), 577-587 (2008-02-07)
5-Hydroxytryptamine (5-HT)(2C) receptor agonists hold promise for the treatment of obesity. In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT(2C) full agonist. Lorcaserin bound to human and rat
Muhan Jing et al.
Frontiers in pharmacology, 12, 761966-761966 (2021-11-23)
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients' appetite and improve insulin sensitivity and

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.